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Background: In the past ten years there have been three separate outbreaks of fungal contaminated steroid
injections from compounding pharmacies. The 2012 outbreak of central nervous system fungal infections
associated with contaminated methylprednisolone produced by a United States compounding pharmacy has led
to 750 infections (151 with meningitis and paraspinal infections and 325 cases with paraspinal infections without
meningitis) and 64 deaths as of October 23, 2013. Exserohilum rostratum has been the predominant pathogen
identified by culture, polymerase chain reaction or antibody tests. According to previous reports, cerebral
involvement with phaeohyphomycosis has a high risk of morbidity and mortality.
Case presentation: We report a 41 year-old Caucasian woman who received a lumbar methylprednisolone
injection from a contaminated lot in August 2012. She was diagnosed with fungal meningitis by cerebrospinal fluid
pleocytosis and positive (1, 3) beta-D-glucan after cultures and polymerase chain reaction were negative. Two weeks
after onset of therapy, she developed a 4.1 mm superior cerebellar artery mycotic aneurysm associated with new
stroke symptoms, which resolved with thirty-two weeks of antifungal treatment.
Conclusions: This is the rare case report of successful medical management of a cerebral mycotic aneurysm with
stroke symptoms related to a presumed phaeohyphomycosis in an immunocompetent individual. Further studies
are needed to determine the utility of cerebrospinal fluid (1, 3) beta-D-glucan in diagnosing and monitoring
patients with meningitis thought to be related to fungal infection.
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In the past ten years there have been three separate out-
breaks of fungal contaminated steroid injections from
compounding pharmacies in the United States [1-3]. The
2012 outbreak of central nervous system (CNS) fungal in-
fections associated with contaminated methylprednisolone
produced by a compounding pharmacy has led to 751 in-
fections (233 with meningitis alone, 151 with meningitis
and paraspinal infections and 325 cases with paraspinal
infections without meningitis) and 64 deaths as of Octo-
ber 23, 2013 [2,4,5]. Exserohilum rostratum has been the
predominant pathogen identified by culture, polymerase* Correspondence: dsulliva@jhsph.edu
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unless otherwise stated.chain reaction (PCR) or antibody tests with 85% (153/180)
of the identified isolates [6,7].
According to previous reports, cerebral involvement
with phaeohyphomycosis has a high risk of morbidity
and mortality [8,9]. Here we report the medical manage-
ment and resolution of a fungal meningitis case associ-
ated with development of a mycotic aneurysm.
Case presentation
A 41 year-old Caucasian woman with a history of
Ehlers-Danlos type III syndrome, migraine headaches,
and sciatica received a lumber 4/lumbar 5 translaminar
epidural steroid injection from a contaminated com-
pounded steroid lot (06292012@26) on August 31, 2012
[10]. Seventeen days after her injection, she developed
headaches, nausea and vomiting and was diagnosed with
sinusitis and migraines. Thirty-seven days after injection
she received a notification letter of exposure from theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gency department. She underwent a lumbar puncture
(LP) showing pleocytosis (Table 1). Given these results
and otherwise negative workup for alternative etiologies,
and in the context of the ongoing contaminated steroid
outbreak, she was treated with liposomal amphotericin B
(5 mg/kg daily) and voriconazole (5 mg/kg IV q12h) for
presumptive fungal meningitis. Repeat lumbar puncture
(LP) performed one week after initiation of therapy
showed no increase in pleocytosis (Table 1). She was
discharged from the outside facility three days later on
oral voriconazole, though medication initiation was de-
layed due to medication supply issues.
She presented to this hospital three days after dis-
charge with fevers, worsening headache and vomiting.
She also had developed new left face, hand and foot
numbness. Neurological exam revealed diminished light
touch and temperature sensation in the region of the left
cranial trigeminal nerve, mandibular division, left hand
and the dorsal aspect of left foot, as well as 4/5 strength
on left foot dorsiflexion. Brain magnetic resonance im-
aging (MRI) on October 21 showed evidence of acute in-
farct at the right pons with the suggestion of a prominent
vessel in the right perimesencephalic cistern suspicious for
a mycotic aneurysm and evidence of diffuse vasculopathy
of the vertebrobasilar arteries, (Figure 1). A computed tom-
ography (CT) angiography showed a 4.1 mm aneurysm at
the right superior cerebellar artery in the right perimesen-
cephalic cistern (Figure 2A). Repeat LP showed stable pleo-
cytosis (Table 1). She was restarted on liposomal
amphotericin B (7.5 mg/kg daily) and intravenous vorico-
nazole (6 mg/kg q12h).
One week later, repeat brain MRI with gadolinium
showed evidence on gradient echo sequences of sub-
arachnoid signal changes consistent with either blood or
inflammation in the prepontine cistern, bilateral occipi-
tal horns, and right hemispheric subarachnoid space.
The aneurysm appeared stable in size, though more ir-
regular. In consultation with Neurosurgery, the risks ofTable 1 Serial cerebrospinal fluid analysis
Date OP Total WBC (x 106/L) N% L% M% Glu m
Oct 8 ND 353 38 48 14 43
Oct 15 ND 225 67 25 8 43
Oct 21 17 240 69 27 4 44
Nov 9 ND 140 41 38 21 43
Dec 10
Jan 21
Jan 26 ND 8 25 0 75 54
Feb 4
Jun 19
Table Footnotes: OP-opening pressure, WBC-white blood cells, N-neutrophils, L-lym
protein, FCx-Fungal cultures, Cr-creatinine, ND- not done.operation given the location, size and friable appearance
of the aneurysm outweighed the potential benefits of
surgical intervention. She had a MRI lumbar spine due
to new onset urinary retention during her hospitalization
(November 13th) which showed evidence of arachnoiditis
affecting intrathecal and bilateral dorsal extradural com-
ponents. The patient underwent a repeat LP on Novem-
ber 9th, now 10 weeks after initial contaminated steroid
injection, which indicated persistent pleocytosis (Table 1).
The voriconazole level, 5 days after reinitiation of 6 mg/kg
intravenous therapy was less than 1 mcg/mL and dosing
was increased to 9 mg/kg dosing despite presence of hal-
lucinations on the lower nontherapeutic dose begun at
this second hospitalization on October 21st.
Prior to discharge repeat CT angiography showed slight
decrease in aneurysm size to 3.8 mm and no subarachnoid
hemorrhage (not shown). Three months into therapy the
right superior cerebral artery aneurysm was diminished
but not resolved in February, 2013 (Figure 2B).
Microbiological studies resulted in negative fungal
cerebrospinal fluid (CSF) cultures on October 8, 15, 21
and Novemberz 9 at the hospital clinical laboratory.
CSF PCR was also negative for fungal and Exserohilum
species detection at Centers for Disease Control and
Prevention (CDC) [7]. Archival CSF from the three
October and single November LPs held in the state lab
were retrospectively evaluated for (1,3)-β-D-glucan
(BDG), with results showing levels greater than 500 pg/mL
(positive >80 pg/mL).
She received a total of 32 weeks of antifungal treat-
ment, initially with 14 weeks of combined voriconazole
and liposomal amphotericin B, followed by 8 weeks of
voriconazole alone due to renal insufficiency from lipo-
somal amphotericin B, followed by 4 weeks of combined
therapy and ending with 6 weeks of liposomal amphoter-
icin B alone which was discontinued secondary to renal
dysfunction, nausea, emesis and myalgias. She completed
26 weeks of voriconazole and 24 weeks of liposomal
amphotericin B. Magnetic resonance angiography (MRA)g/dL Prot mg/dL ESR/CRP BDG pg/mL FCx PCR Cr
85 >500 Neg
79 >500 Neg
138 >500 Neg 1.1






phocytes, M-monocytes, ESR- erythrocyte sedimentation rate, CRP- C-reactive
A B 
C 
Figure 1 Right pons ischemia. A. Diffusion weighted MRI showing restriction in right pons (arrow) consistent with ischemia on October
29, 2012. B. Contrast CT with right superior cerebellar artery (arrow) enhancement. C. Reformatted 3-D CT angiography on Oct 29, 2012 showing
diffuse vasculopathy at the basilar arteries and bilateral vertebral arteries.
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showed resolution of the aneurysm. Her symptoms re-
solved forty weeks after onset. MRA was performed at the
end of antifungal therapy, which showed resolution of the
aneurysm. An August, 2013 CTA performed 3 months
after discontinuation of all antifungal therapy did not
show any recurrence of aneurysm (Figure 3). More than a
year after onset of symptoms and 6 months off therapy
she remains well and is considered a “cure”.
Conclusions
This case reflects many challenges of diagnosis and
treatment of cerebral phaeohyphomycosis. All of her
CSF cultures and PCR tests were negative. CSF testing
for BDG has not been clinically validated, although BDG
levels were elevated in this case [11,12]. BDG is a glu-
cose polymer, a cell wall component of most fungal or-
ganisms. The Fungitell assay (Associates of Cape Cod,
Inc., Falmouth, MA) has been approved by the US Food
and Drug Administration for detection of BDG in hu-
man serum and has shown utility in the diagnosis of infec-
tions caused by several fungal pathogens [8,9]. Ongoingstudies are examining the utility of CSF BDG in CNS fun-
gal infections. Though this patient did not have findings
of systemic fungemia, the titers were elevated on multiple
occasions, likely reflecting true positive results.
Given the close proximity of the aneurysm to the ac-
tive inflammation seen on brain MRI, its location distal
to a vessel juncture and its poorly defined neck, fusiform
and irregular shape, we felt that her aneurysm was my-
cotic in nature. Patients with unruptured mycotic aneu-
rysms are generally managed with medical therapy alone
though there is general consensus that if the mycotic
aneurysm enlarges, fails to resolve or ruptures during
medical treatment, they should be considered for surgery
or endovascular treatment [13]. To our knowledge this
is the rare case report of successful medical management
of a cerebral mycotic aneurysm related to phaeohypho-
mycosis in an immunocompetent individual. A recent
report detailed three cases of fungal meningitis related
to the outbreak that presented with symptoms consistent
with ischemic stroke; two cases were found to have my-
cotic aneurysms on postmortem examination and none
had mycotic aneurysm noted on imaging [14]. The two
A 
B 
Figure 2 Superior cerebellar artery aneurysm. Reformatted 3-D CT
angiography of right superior cerebellar artery showing A. a 4.2 mm
aneurysm (arrow) on Nov 5, 2012 and later B. with significant resolution of
aneurysm (arrow) after 3 months of amphotericin therapy on Feb 5, 2013.
A 
B 
Figure 3 Resolution of superior cerebellar artery aneurysm. CT
angiography from neck coronal slices in October, 2012 A. showing
prominent aneurysm (arrow) involving the right superior cerebellar
artery with B. follow-up on August 2013 indicating resolution of the
aneurysm (arrow).
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three patients had common risk factors for ischemic
events; our patient had no traditional risk factors for
stroke and had both acute infarct and aneurysm forma-
tion noted on imaging with improvement in symptoms
and size of aneurysm at one year of follow up.
Voriconazole is known to have erractic pharmacokinetics
and despite new onset hallucinations, the 6 mg/kg dosing
was not therapeutic emphasizing the importance of
mandatory drug levels in all patients on therapy [15]. This
patient had a subtherapeutic voriconazole level obtained
5 days after initiation. She was on no medications known to
decrease serum levels of voriconazole; this highlights the
nonlinear pharmacokinetics of voriconazole and empha-
sizes the need to monitor levels closely. We can only specu-
late that the patient, a young, nonobese otherwise healthy
adult, metabolized voriconazole at an increased rate. We
were able to complete 23 weeks of liposomal amphotericin
and 26 weeks of voriconazole with 17 weeks of overlap.
While there has been some preclinical data suggesting an-
tagonism between liposomal amphotericin and voricona-
zole, we elected to treat with dual therapy in accordancewith CDC guidance and the severity of her symptoms.
Normalization of pleocytosis, erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) occurred after
12 weeks of therapy. Despite maximum medical therapy,
she developed a new 1 cm epidural abscess at the local in-
jection site 4 months into therapy that was sterile by fungal
and bacterial culture when surgically removed. Additionally,
our patient’s course was complicated by arachnoiditis and
adverse drug events (hepatitis, renal insufficiency), despite
being otherwise young and healthy.
This case emphasizes the ongoing need for close
monitoring of patients exposed during the 2012 fungal
meningitis outbreak. Our patient developed meningitis,
cerebral mycotic aneurysm, an acute infarct, epidural
abscess, arachnoiditis, and stroke symptoms all as a re-
sult of the contaminated injection; her course was compli-
cated by adverse drug events necessitating discontinuation
of therapy. Complications seen in our case occurred sev-
eral weeks after initial infection during combination anti-
fungal therapy. Recommendations have evolved over time
concerning appropriate duration of therapy, but no guid-
ance exists on serial imaging. This underscores the need
to follow patients clinically and radiographically given the
difficulties in relying on laboratory evaluation alone. Fur-
ther studies are needed to determine the utility of CSF
BDG in diagnosing and monitoring patients with meningi-
tis thought to be related to fungal infection.
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